TALAPRO-2: A study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency
https://www.facingourrisk.org/research-clinical-trials/study/98/talapro-2-a-study-assessing-the-study-drug-enzalutamide-vs-placebo-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-dna-damage-repair-ddr-deficiency
Clinicaltrials.gov identifier:
NCT03395197 (https://clinicaltrials.gov/show/NCT03395197)
About the Study
TALAPRO-2 is a study for men who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) which means that hormone therapies, one of the main treatment options for this type of cancer, have no effect and the tumor has spread to other parts of the body. NOTE: This study is no longer enrolling patients.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To:
NOTE: This study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.